Welcome to the World of Biotech Finance

Abivax Enters ATM Program on Nasdaq

PARIS, France, November 19, 2024 – 10:30PM CET

Abivax SA, a leading biotechnology company, has made a groundbreaking announcement by establishing an At-the-Market (ATM) Program on Nasdaq. This program allows Abivax to issue and sell ordinary shares in the form of American Depositary Shares (ADS), with aggregate gross sales proceeds of up to $150,000,000. The Company has partnered with Piper Sandler & Co. to act as the sales agent for this initiative.

Abivax is known for its focus on developing therapeutics that modulate the inflammatory response in patients with chronic inflammatory diseases. By harnessing the body’s natural regulatory mechanisms, the Company aims to provide innovative solutions for those in need.

The implementation of the ATM Program marks a significant milestone for Abivax, opening up new opportunities for growth and expansion. The timing of the issuances will be determined by various factors, with the potential to attract a diverse range of investors.

Impact on You

As a stakeholder in the biotech industry, the establishment of Abivax’s ATM Program could have a direct impact on your investment portfolio. The ability to purchase ADSs in Abivax provides you with a unique opportunity to support a company that is at the forefront of developing cutting-edge therapeutics.

By investing in Abivax through the ATM Program, you not only stand to benefit from potential financial returns but also contribute to the advancement of innovative treatments for chronic inflammatory diseases. Your support can make a difference in the lives of patients seeking relief from these conditions.

Global Implications

The launch of Abivax’s ATM Program on Nasdaq has far-reaching implications for the biotech industry and the global healthcare landscape. As Abivax continues to develop novel therapeutics that target the inflammatory response, the potential impact on patient outcomes and disease management is significant.

By raising funds through the ATM Program, Abivax can accelerate its research and development efforts, bringing new treatments to market more quickly. This could ultimately lead to improved patient care and better outcomes for individuals living with chronic inflammatory diseases worldwide.

Conclusion

In conclusion, Abivax’s decision to establish an ATM Program on Nasdaq represents a key moment in the Company’s growth trajectory. By leveraging this innovative financing strategy, Abivax is positioning itself for future success and paving the way for advancements in biotechnology that have the potential to transform patient care on a global scale.